phenox

In 2005, the founders of phenox recognized a critical gap in the treatment of neurovascular diseases, particularly stroke - the second leading cause of death worldwide. Traditional surgical approaches were invasive and carried significant risks for patients suffering from both ischemic and hemorrhagic strokes. This realization drove the development of breakthrough, minimally invasive endovascular technologies that could fundamentally transform how physicians treat these life-threatening conditions.

Since its founding in 2005, phenox has developed into a global innovation leader in neurovascular devices for the interventional treatment of strokes. The company has built a broad product portfolio covering both ischemic and hemorrhagic stroke treatment, as well as access and delivery solutions. Key product lines include the p64/p48 range of flow diverters for the treatment of intracranial aneurysms and the pRESET range of stent retrievers for mechanical thrombectomy of ischemic strokes. phenox has also developed proprietary coating technologies for enhancing permanent and short-term implants. In April 2022, phenox was acquired by Wallaby Medical for approximately EUR 500 million, creating a global leader in neurovascular technologies with products marketed in over 45 countries worldwide. The company maintains subsidiaries in Italy, the UK, Ireland, and the United States, with headquarters in Bochum, Germany.